Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Products & comparisons
Product source

Lipo NR capsule label record: nicotinamide riboside 300 mg per serving

The DSLD record for Lipo NR by Renue By Science lists a capsule form and 300 mg nicotinamide riboside per labelled serving. It is a label declaration only, not evidence of efficacy, safety or approval. [1]

Automatic summary · not editorially reviewed

Label · NIH DSLD
Lipo NROriginal label · NIH DSLD
Lipo NR

FROM THE ORIGINAL LABEL

A closer look at the product

Pack contents
90 Vegetarian Capsule(s)
Label serving
1 Capsule(s)
Servings per container
90
Barcode / SKU
6 56165 85234 5
Open original label (PDF)
Ingredients & declared amounts1

Amounts from the label, per specified serving. These are manufacturer declarations, not a personal dosage recommendation.

IngredientAmountPer label serving
Nicotinamide Riboside300 mg1 Capsule(s)

Other ingredients: Cellulose, Sunflower Lecithin, Rice Flour, Microcrystalline Cellulose

Source: National Institutes of Health, Office of Dietary Supplements · Dietary Supplement Label Database. Label snapshot; packaging and formulation may have changed.

The key findings

  1. DSLD record 319022 covers Lipo NR by Renue By Science, entered 2024-12-21. [1]

  2. The label declares a capsule form and 300 mg nicotinamide riboside per labelled serving. [1]

  3. DSLD inclusion does not establish efficacy, safety, FDA approval, laboratory verification or retail availability. [1]

The source at a glance

Brand
Renue By Science
Form
Capsule
Pack contents
90 Vegetarian Capsule(s)
Label serving
1 Capsule(s)
Ingredients listed
Nicotinamide Riboside
Record type / format
Dietary supplement label/database record
Scope / context
The dietary supplement product Lipo NR by Renue By Science, as described in DSLD record 319022.
Summary based on
Product label / database record

Lipo NR record in the NIH DSLD

This is record 319022 in the Dietary Supplement Label Database of the NIH Office of Dietary Supplements. The product label name is Lipo NR, the declared brand is Renue By Science, and the label entered the database on 2024-12-21. That date is when the label was entered, not a product launch date. The database places the product in its Vitamin category.

Supporting source [1]

Declared capsule form and 300 mg nicotinamide riboside

The label declares the physical form as a capsule. The only declared ingredient with an amount in this record is nicotinamide riboside, listed at 300 mg per labelled serving. These are label facts as recorded in the database; the record gives no personal dosing advice and no serving recommendation.

Supporting source [1]

What this label snapshot does not establish

The record describes label declarations only. Inclusion in the DSLD does not establish efficacy, safety, FDA approval, laboratory verification or current retail availability. No independent product testing, price or batch certificate is supplied. The amounts are label facts, not personal dosing advice.

Supporting source [1]

How to interpret this

Product label record; not evidence of efficacy or approval. The record describes label declarations only; no independent testing, price or batch certificate is supplied, and the entry date is not a launch date.

Based on a product label or database record. This does not establish effectiveness, independent batch testing, approval or current availability.

Source & supporting passages

[1]
Lipo NR

Renue By Science · dsld.od.nih.gov

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    Date this label entered DSLD: 2024-12-21
  2. Finding 2 ↑

    Nicotinamide Riboside: 300 mg per labelled serving
  3. Finding 3 ↑

    DSLD inclusion does not establish efficacy, safety,

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…